| Authors: |
Hermans C; Cliniques universitaires saint-Luc, Université catholique de Louvain (UCLOuvain), Brussels, Belgium., Valentino LA; National Bleeding Disorders Foundation, New York City, New York, USA.; Hemophilia and Thrombophilia Center, Rush University, Chicago, Illinois, USA., Thornburg CD; Department of Pediatrics, University of California San Diego, La Jolla, California, USA.; Hemophilia and Thrombosis Treatment Cente, Rady Children's Hospital San Diego, San Diego, California, USA., Unzu C; DNA&RNA Medicine Division, CIMA-Universidad de Navarra, IdisNA, Pamplona, Spain., Kay MA; Pediatrics - Human Gene Therapy, Stanford University, Stanford, California, USA., Peyvandi F; Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy., Smith P; Utah Center for Bleeding and Clotting Disorders, Salt Lake City, Utah, USA., Miesbach W; Department of Haemostaseology, University Hospital Frankfurt, Frankfurt, Germany., McKeown W; Care of Elderly Medicine, Antrim Area Hospital, Antrim, Northern Ireland., Pierce GF; World Federation of Hemophilia, Montreal, Quebec, Canada., Khair K; Haemnet, London, UK., Pipe SW; Pediatric Hematology-Oncology, University of Michigan, Ann Arbor, Michigan, USA., Starcevic K; Language Strategy, Maslansky and Partners, New York City, New York, USA., Pillai M; Language Strategy, Maslansky and Partners, New York City, New York, USA., Jones M; Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA., Chiao M; Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA., Antonino I; Intellia Therapeutics, Inc., Cambridge, Massachusetts, USA., Kessler C; Medicine and Pathology, Georgetown University, Washington, District of Columbia, USA. |
